Gilead Sciences has agreed to pay $45 million to settle allegations brought by the Texas attorney general involving claims of Medicaid kickbacks. The settlement resolves charges that the payments improperly influenced prescriptions covered by the Texas Medicaid program.
Both outlets frame the matter as a legal resolution tied to alleged conduct affecting how Medicaid prescriptions are influenced. Seeking Alpha emphasizes the settlement amount and the fact it is with Texas over a “kickback scheme,” while STAT highlights that the kickback allegations are tied to claims that prescriptions reimbursed through Texas Medicaid were improperly influenced. Other details beyond the settlement and the general allegation are not included in the provided summaries.
